By SPC News Staff
The FDA has approved infliximab-abda (Renlexis, Samsung Bioepis), another biosimilar of infliximab (Remicade, Janssen Biotech) for all eligible indications.
Infliximab-abda, a tumor necrosis factor (TNF) blocker, will be indicated for the treatment of adult and pediatric Crohn’s disease (rare), adult ulcerative colitis, pediatric ulcerative colitis (rare), rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis and adult plaque psoriasis.
Infliximab-abda is